If you have been reading about HPLC-MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-07-21. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Concerns about possible adverse effects are that intravenous high-dose vitamin C leads to a supraphysiological level of vitamin C followed by oxidative degradation to dehydroascorbic acid and hence to oxalate, increasing the risk of oxalate kidney stones and oxalate nephropathy. The risk may be higher in people with renal impairment, as kidneys efficiently excrete excess vitamin C. Second, treatment with high dose vitamin C should be avoided in patients with glucose-6-phosphate dehydrogenase deficiency as it can lead to acute hemolysis. Third, treatment might interfere with the accuracy of glucometer measurement of blood glucose levels, as both vitamin C and glucose have similar molecular structure, which could lead to false high blood glucose readings. Despite all these concerns, meta-analyses of patients in intensive care for sepsis, septic shock, COVID-19 and other acute conditions reported no increase in new-onset kidney stones, acute kidney injury or requirement for renal replacement therapy for patients receiving short-term, high-dose, intravenous vitamin C treatment. This suggests that intravenous vitamin C is safe under these short-term applications.
In case of above-normal intraocular pressure, the mechanism of open-angle glaucoma is believed to be the impeded exit of aqueous humor through the trabecular meshwork, while in closed-angle glaucoma, the iris blocks the trabecular meshwork. Diagnosis is achieved by performing an eye examination. Often, the optic nerve shows an abnormal amount of cupping.
β-Hydroxy β-methylbutyric acid is a monocarboxylic β-hydroxy acid and natural product with the molecular formula C5H10O3. At room temperature, pure β-hydroxy β-methylbutyric acid occurs as a transparent, colorless to light yellow liquid which is soluble in water. β-Hydroxy β-methylbutyric acid is a weak acid with a pKa of 4.4. Its refractive index (
Sources: en.wikipedia.org
The ethical principle of primum non-nocere ("first, do no harm") guides the trial, and if an investigator believes the study treatment may be harming subjects in the study, the investigator can stop participating at any time. On the other hand, investigators often have a financial interest in recruiting subjects, and could act unethically to obtain and maintain their participation. The local investigators are responsible for conducting the study according to the study protocol, and supervising the study staff throughout the duration of the study. The local investigator or his/her study staff are also responsible for ensuring the potential subjects in the study understand the risks and potential benefits of participating in the study. In other words, they (or their legally authorized representatives) must give truly informed consent. Local investigators are responsible for reviewing all adverse event reports sent by the sponsor. These adverse event reports contain the opinions of both the investigator (at the site where the adverse event occurred) and the sponsor, regarding the relationship of the adverse event to the study treatments. Local investigators also are responsible for making an independent judgment of these reports, and promptly informing the local IRB of all serious and study treatment-related adverse events. When a local investigator is the sponsor, there may not be formal adverse event reports, but study staff at all locations are responsible for informing the coordinating investigator of anything unexpected.
==== Metabolism ==== The metabolism of tiagabine has not been fully characterized. In any case, it is metabolized by at least two known pathways. One is thiophene ring oxidation resulting in 5-oxotiagabine and the other is glucuronidation. 5-Oxotiagabine is said not to contribute to the pharmacodynamics of tiagabine. In-vitro studies suggest that tiagabine is metabolized primarily by the cytochrome P450 enzyme CYP3A4, although involvement of other enzymes like CYP1A2, CYP2D6, or CYP2C19 has not been excluded. Two other metabolites of tiagabine have yet to be identified.
== Use and effects == In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin and colleagues stated that doses of 1 to 3 mg orally produced clear threshold effects and that it was active at a dose of slightly more than twice that of DOM. It was stated that 10 mg DOBU was required to produce hallucinogenic effects. The drug's duration was listed as "very long". There was limited investigation of its qualitative effects. However, in PiHKAL, at the assessed doses of 2.2 mg and 2.8 mg, it was described as producing paresthesia and difficulty sleeping with few other effects. The effects of higher doses of DOBU have not been described beyond them producing hallucinogenic effects.
A definitive diagnosis is made after based on growth hormone concentrations or increased IGF-1 levels. In male dogs with no history of progestogen administration the possibility of a pituitary tumour needs to be examined via CT/MRI. In cats with difficult to manage diabetes but no other signs of hypersomatotropism, the potential for other causes of poor glycaemic control need to be considered.
Sources: en.wikipedia.org
== Background == The match was a repeat of the 1973 final, making it the fourth repeated final pairing. Ajax won the 1973 final 1–0. Ajax was defending the title, having won in 1995 when they defeated Milan 1–0. Juventus had not featured in the Champions League for nine years until this edition of the tournament. Juventus reached their fourth final. In the semi-finals, Juventus eliminated French side Nantes, with a 2-0 victory in the first leg at home, and 3–2 defeat in the return leg. Previously Juventus won the final in 1985, and lost in 1973 and 1983. Ajax reached their sixth final. In the semi-finals, Ajax eliminated Greek side Panathinaikos; they lost the first leg 1–0 at home, but won 3–0 in the second leg. Previously Ajax won the finals in 1971, 1972, 1973 and 1995, and lost in 1969. Juventus entered the final as 1995–96 Serie A runners-up to Milan, as well as 1995 Supercoppa Italiana winners. Ajax entered the final as 1995–96 Eredivisie champions, 1995 Dutch Supercup winners, 1995 UEFA Super Cup and 1995 Intercontinental Cup winners.
Since 2007, Israel had implemented a strict land and sea blockade that had prevented items such as food and medicine from moving into the Gaza Strip, with the health system struggling before the war. Ahmed al-Fara, the head of pediatrics at Nasser Medical Complex in Khan Younis, stated due to the lack of water during the war, he was witnessing the "most serious epidemic of gastroenteritis" among children he had ever seen. Catherine M. Russell, the executive director of UNICEF, toured Gaza on 15 November 2023, stating many children were lacking medical care. On 28 December, UNOCHA stated 50 percent of all children in the Gaza Strip were experiencing dehydration, malnutrition, respiratory and skin diseases. Cases of diarrhea in children under the age of five has increased by about 2,000% since 7 October per a UNICEF report. A UN spokesperson indicated that between 7 October 2023 and 4 January 2024, disease had skyrocketed in Gaza with more than 400,000 cases of infectious disease reported, which included about 180,000 people with upper respiratory infections and more than 136,000 cases of diarrhea, with half of cases presenting in children under 5. By July 2024, WHO stated more than 150,000 people had contracted skin infections, with malnourished children most susceptible due to their weakened immune systems. According to statistics published by the World Health Organization (WHO), in January 2024, only about 30% of medics were still working due to the widespread effects of the war in Gaza.
=== Foot surgeries === Generally, foot surgery is usually reserved for patients with a walking or ambulatory potential. Foot surgery may also be indicated to assist brace and orthosis fitting and hence promote supported standing. The most common foot deformity in arthrogryposis is club feet or talipes equinovarus. In the early years of life the serial casting according to the Ponseti method usually yields good results. The Ponseti method can also be used as a first line treatment in older and more resistant cases. In such severe and neglected cases bony surgery in the form of foot osteotomies and arthrodesis is usually indicated. It is usually accompanied by soft tissue surgery in the form of release of contracted tendon and capsular structures. In older patients near skeletal maturity joint fusion or arthrodesis may be indicated as well. Less frequent patients with arthrogryposis may develop congenital vertical talus also known as rocker bottom foot. Similarly, congenital vertical talus is classically managed by serial casting according to the reversed Ponseti method. Resistant or recurrent cases may be offered an extensive soft tissue release. However this is fraught with risk of foot stiffness and pain in the long term. Talectomy or excision of the talus to give room for creation of plantigrade foot has been practiced. Naviculectomy or midtarsal resection arthroplasty represents a less invasive option with satisfactory short-term results.
'funded by a pharmaceutical company (Servier) and two of its authors are employees of that company', which may bias the results. The study authors' note: "emotional blunting is reported by nearly half of depressed patients on antidepressants and that it appears to be common to all monoaminergic antidepressants not only SSRIs". Additionally, they note: "The OQuESA scores are highly correlated with the HAD depression score; emotional blunting cannot be described simply as a side-effect of antidepressant, but also as a symptom of depression. More emotional blunting is associated with a poorer quality of remission.
== Industrial use == Butane-1,4-diol is used industrially as a solvent and in the manufacture of some types of plastics, elastic fibers and polyurethanes. In organic chemistry, 1,4-butanediol is used for the synthesis of γ-butyrolactone (GBL). In the presence of phosphoric acid and high temperature, it dehydrates to the important solvent tetrahydrofuran. At about 200 °C in the presence of soluble ruthenium catalysts, the diol undergoes dehydrogenation to form butyrolactone. It is used to synthesize 1,4-butanediol diglycidyl ether which is then used as a reactive diluent for epoxy resins. 1,4-Butanediol is used in the production of polybutylene terephthalate (PBT) plastic. World production of butane-1,4-diol was claimed to be about one million metric tons per year and market price is about US$2,000 (€1,600) per ton in 2005. In 2013, worldwide production was claimed to be billions of pounds (consistent with approximately one million metric tons). Almost half of it is dehydrated to tetrahydrofuran to make fibers such as Spandex. The largest producer is BASF.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.